CY1114590T1 - Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα - Google Patents
Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγοναInfo
- Publication number
- CY1114590T1 CY1114590T1 CY20131100994T CY131100994T CY1114590T1 CY 1114590 T1 CY1114590 T1 CY 1114590T1 CY 20131100994 T CY20131100994 T CY 20131100994T CY 131100994 T CY131100994 T CY 131100994T CY 1114590 T1 CY1114590 T1 CY 1114590T1
- Authority
- CY
- Cyprus
- Prior art keywords
- peptides
- present
- expressing tumor
- related antigens
- peptide vaccines
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 229940023041 peptide vaccine Drugs 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 5
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 5
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 206010001497 Agitation Diseases 0.000 abstract 1
- 102100024153 Cadherin-15 Human genes 0.000 abstract 1
- 102100036109 Dual specificity protein kinase TTK Human genes 0.000 abstract 1
- 101150078651 Epha4 gene Proteins 0.000 abstract 1
- 102100021616 Ephrin type-A receptor 4 Human genes 0.000 abstract 1
- 101000762242 Homo sapiens Cadherin-15 Proteins 0.000 abstract 1
- 101000714553 Homo sapiens Cadherin-3 Proteins 0.000 abstract 1
- 101000659223 Homo sapiens Dual specificity protein kinase TTK Proteins 0.000 abstract 1
- 101000839066 Homo sapiens Hypoxia-inducible lipid droplet-associated protein Proteins 0.000 abstract 1
- 101001054725 Homo sapiens Inhibin beta B chain Proteins 0.000 abstract 1
- 101001027621 Homo sapiens Kinesin-like protein KIF20A Proteins 0.000 abstract 1
- 101001112162 Homo sapiens Kinetochore protein NDC80 homolog Proteins 0.000 abstract 1
- 101000817237 Homo sapiens Protein ECT2 Proteins 0.000 abstract 1
- 102100028891 Hypoxia-inducible lipid droplet-associated protein Human genes 0.000 abstract 1
- 102100027003 Inhibin beta B chain Human genes 0.000 abstract 1
- 102100037694 Kinesin-like protein KIF20A Human genes 0.000 abstract 1
- 102100023890 Kinetochore protein NDC80 homolog Human genes 0.000 abstract 1
- 102100040437 Protein ECT2 Human genes 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 150000001413 amino acids Chemical class 0.000 abstract 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 abstract 1
- 230000006806 disease prevention Effects 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000002018 overexpression Effects 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/422—Ephrin Receptors [Eph]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Hematology (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Dispersion Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90294907P | 2007-02-21 | 2007-02-21 | |
| EP08710443.6A EP2121731B1 (en) | 2007-02-21 | 2008-02-21 | Peptide vaccines for cancers expressing tumor-associated antigens |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1114590T1 true CY1114590T1 (el) | 2016-10-05 |
Family
ID=39709837
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20131100994T CY1114590T1 (el) | 2007-02-21 | 2013-11-08 | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα |
| CY20141101067T CY1115841T1 (el) | 2007-02-21 | 2014-12-18 | Εμβολια πεπτιδιου παραγομενα απο epha4 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20141101067T CY1115841T1 (el) | 2007-02-21 | 2014-12-18 | Εμβολια πεπτιδιου παραγομενα απο epha4 |
Country Status (27)
| Country | Link |
|---|---|
| EP (20) | EP2465866A3 (enExample) |
| JP (6) | JP5239103B2 (enExample) |
| KR (8) | KR20150116463A (enExample) |
| CN (4) | CN102863514B (enExample) |
| AR (1) | AR068302A1 (enExample) |
| AU (1) | AU2008218463B2 (enExample) |
| BR (1) | BRPI0808421B1 (enExample) |
| CA (3) | CA2678755C (enExample) |
| CO (1) | CO6190536A2 (enExample) |
| CY (2) | CY1114590T1 (enExample) |
| DK (3) | DK2121731T3 (enExample) |
| ES (6) | ES2435194T3 (enExample) |
| HR (3) | HRP20131044T1 (enExample) |
| IL (10) | IL200478A (enExample) |
| MX (4) | MX337417B (enExample) |
| MY (2) | MY173379A (enExample) |
| NZ (4) | NZ579768A (enExample) |
| PH (1) | PH12014501642B1 (enExample) |
| PL (3) | PL2465864T3 (enExample) |
| PT (2) | PT2465864E (enExample) |
| RU (1) | RU2464275C2 (enExample) |
| SG (3) | SG179402A1 (enExample) |
| SI (3) | SI2121731T1 (enExample) |
| TW (5) | TWI615403B (enExample) |
| UA (1) | UA100372C2 (enExample) |
| WO (1) | WO2008102557A1 (enExample) |
| ZA (1) | ZA200905881B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1882698B (zh) | 2003-08-20 | 2011-05-25 | 肿瘤疗法科学股份有限公司 | 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶 |
| AU2008290060B2 (en) * | 2007-08-20 | 2014-04-24 | Oncotherapy Science, Inc. | CDH3 peptide and medicinal agent comprising the same |
| WO2010001585A1 (en) | 2008-06-30 | 2010-01-07 | Oncotherapy Science, Inc. | Anti-cdh3 antibodies labeled with radioisotope label and uses thereof |
| TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| TW201008574A (en) | 2008-08-19 | 2010-03-01 | Oncotherapy Science Inc | INHBB epitope peptides and vaccines containing the same |
| MX2011004176A (es) * | 2008-10-22 | 2011-09-21 | Oncotherapy Science Inc | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo. |
| TWI500932B (zh) | 2008-12-05 | 2015-09-21 | Oncotherapy Science Inc | Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗 |
| AU2009332389A1 (en) * | 2008-12-24 | 2011-07-14 | Oncotherapy Science, Inc. | C1orf59 peptides and vaccines including the same |
| TW201102081A (en) * | 2009-05-11 | 2011-01-16 | Oncotherapy Science Inc | TTK peptides and vaccines including the same |
| US8703808B2 (en) | 2009-06-23 | 2014-04-22 | Centre National De La Recherche Scientifique | Use of derivatives of indoles for the treatment of cancer |
| DK2519542T3 (en) | 2009-12-28 | 2019-01-14 | Onco Therapy Science Inc | ANTI-CDH3 ANTIBODIES AND APPLICATIONS THEREOF. |
| ES2575160T3 (es) | 2010-03-15 | 2016-06-24 | The Board Of Trustees Of The University Of Illinois | Inhibidores de las interacciones que unen la subunidad alfa de la beta integrina-proteína G |
| TW201627003A (zh) * | 2010-04-02 | 2016-08-01 | 腫瘤療法 科學股份有限公司 | Ｅｃｔ２胜肽及含此胜肽之疫苗 |
| AU2011336019B2 (en) | 2010-12-02 | 2016-07-07 | Oncotherapy Science, Inc. | TOMM34 peptides and vaccines including the same |
| HRP20191607T1 (hr) | 2011-12-14 | 2019-12-13 | Univ Texas | Biomarkeri za inaktivaciju kolateralnih gena i ciljevi za terapiju raka |
| KR20140138900A (ko) * | 2012-03-09 | 2014-12-04 | 온코세라피 사이언스 가부시키가이샤 | 펩티드를 포함한 의약 조성물 |
| WO2014010232A1 (en) | 2012-07-10 | 2014-01-16 | Oncotherapy Science, Inc. | Ly6k epitope peptides for th1 cells and vaccines containing the same |
| JP6259983B2 (ja) * | 2012-07-10 | 2018-01-17 | オンコセラピー・サイエンス株式会社 | Ｔｈ１細胞のＫＩＦ２０Ａエピトープペプチドおよびこれを含有するワクチン |
| US9683016B2 (en) | 2012-08-31 | 2017-06-20 | Genestem Co., Ltd. | PSF1-derived peptide |
| EP2895600B1 (en) | 2012-09-11 | 2020-02-19 | OncoTherapy Science, Inc. | Ube2t peptides and vaccines containing the same |
| WO2014141652A1 (en) * | 2013-03-11 | 2014-09-18 | Oncotherapy Science, Inc. | Smyd3 peptides and vaccines containing the same |
| TWI658049B (zh) * | 2013-03-12 | 2019-05-01 | 腫瘤療法 科學股份有限公司 | Ｋｎｔｃ２胜肽及含此胜肽之疫苗 |
| US20160166666A1 (en) * | 2013-07-12 | 2016-06-16 | Sumitomo Dainippon Pharma Co., Ltd. | Tumor antigen peptide |
| JP2015227292A (ja) * | 2014-05-30 | 2015-12-17 | 国立大学法人高知大学 | 膵がん細胞浸潤転移抑制ワクチン |
| CN106661119A (zh) | 2014-07-01 | 2017-05-10 | 辉瑞公司 | 双特异性异二聚化双抗体及其用途 |
| EP3848383A3 (en) | 2014-08-04 | 2021-11-03 | Oncotherapy Science, Inc. | Urlc10-derived peptide and vaccine containing same |
| GB201507719D0 (en) * | 2015-05-06 | 2015-06-17 | Immatics Biotechnologies Gmbh | Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers |
| CN104975082B (zh) * | 2015-06-05 | 2018-11-02 | 复旦大学附属肿瘤医院 | 一组用于评估肺癌预后的基因及其应用 |
| JP2019513373A (ja) * | 2016-03-31 | 2019-05-30 | ネオン セラピューティクス， インコーポレイテッド | ネオ抗原およびその使用方法 |
| WO2018090257A1 (zh) * | 2016-11-16 | 2018-05-24 | 深圳华大基因研究院 | 多肽及其应用 |
| DK3573600T3 (da) | 2017-01-25 | 2022-05-09 | Ose Immunotherapeutics | Fremgangsmåde til fremstilling af en stabil emulsion til peptidlevering |
| CN110709508A (zh) * | 2017-03-28 | 2020-01-17 | 朱正仑 | 治疗新生性疾病的方法 |
| EP3666888A4 (en) * | 2017-08-10 | 2021-09-01 | Good T Cells, Inc. | T-CELL ACTIVATION METHOD FOR CANCER TREATMENT |
| CN112812154B (zh) * | 2018-02-15 | 2022-04-05 | 国立大学法人旭川医科大学 | 癌症抗原肽 |
| KR102335916B1 (ko) * | 2019-04-22 | 2021-12-08 | 한국과학기술연구원 | 인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| KR102322832B1 (ko) * | 2019-04-22 | 2021-11-12 | 한국과학기술연구원 | 인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도 |
| CN113117055A (zh) * | 2019-12-31 | 2021-07-16 | 上海细胞治疗集团有限公司 | 一种特异性结合hla-a24分型的多肽组合物及应用 |
| CN117143206B (zh) * | 2023-08-03 | 2024-09-03 | 华南农业大学 | Alv-j mhc-b21限制性表位肽及其筛选方法和应用 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| NZ231899A (en) * | 1985-10-03 | 1991-07-26 | Genentech Inc | Human or porcine inhibin peptide compositions and dna encoding them |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| IL103928A0 (en) * | 1991-12-11 | 1993-04-04 | American Home Prod | Expression of specific immunogens using viral antigens |
| US5804566A (en) | 1993-08-26 | 1998-09-08 | The Regents Of The University Of California | Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides |
| US5679647A (en) | 1993-08-26 | 1997-10-21 | The Regents Of The University Of California | Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides |
| US5739118A (en) | 1994-04-01 | 1998-04-14 | Apollon, Inc. | Compositions and methods for delivery of genetic material |
| EP1464706A3 (en) * | 1994-04-15 | 2004-11-03 | Amgen Inc., | HEK5, HEK7, HEK8, HEK11, EPH-like receptor protein tyrosine kinases |
| US5736524A (en) | 1994-11-14 | 1998-04-07 | Merck & Co.,. Inc. | Polynucleotide tuberculosis vaccine |
| US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
| EP0841945B1 (en) | 1995-08-03 | 2006-03-08 | Rijksuniversiteit te Leiden | Cell derived antigen presenting vesicles |
| US5853719A (en) | 1996-04-30 | 1998-12-29 | Duke University | Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA |
| CA2262006A1 (en) | 1996-07-26 | 1998-02-05 | Sloan-Kettering Institute For Cancer Research | Method and reagents for genetic immunization |
| AU6795898A (en) * | 1997-04-04 | 1998-10-30 | Board Of Regents, The University Of Texas System | Proteins and compositions for modulating mitosis |
| FR2766205B1 (fr) | 1997-07-16 | 2002-08-30 | Inst Nat Sante Rech Med | Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede |
| US20020102542A1 (en) * | 1997-10-07 | 2002-08-01 | Daikichi Fukushima | Polypeptide, cdna encoding the polypeptide, and use of the both |
| US20070014787A1 (en) * | 1998-07-15 | 2007-01-18 | Human Genome Sciences, Inc. | 71 human secreted proteins |
| WO2001029221A2 (en) * | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Proteins and polynucleotides encoding them |
| US6682902B2 (en) * | 1999-12-16 | 2004-01-27 | Schering Aktiengesellschaft | DNA encoding a novel RG1 polypeptide |
| US20030013649A1 (en) * | 2000-01-31 | 2003-01-16 | Rosen Craig A. | Nucleic acids, proteins, and antibodies |
| CN1469926A (zh) * | 2000-03-29 | 2004-01-21 | 科里克萨有限公司 | 治疗和诊断肺癌的组合物和方法 |
| US7118853B2 (en) * | 2000-07-26 | 2006-10-10 | Applied Genomics, Inc. | Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors |
| US6830885B1 (en) * | 2000-08-18 | 2004-12-14 | Phenogene Therapeutiques Inc. | Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature |
| US20090062512A1 (en) * | 2000-10-10 | 2009-03-05 | Hildebrand William H | Comparative ligand mapping from MHC class I positive cells |
| US7919467B2 (en) * | 2000-12-04 | 2011-04-05 | Immunotope, Inc. | Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer |
| CN100400099C (zh) * | 2001-01-04 | 2008-07-09 | 北京迪威华宇生物技术有限公司 | 预防和治疗人前列腺癌的重组蛋白疫苗 |
| US20040236091A1 (en) * | 2001-03-28 | 2004-11-25 | Chicz Roman M. | Translational profiling |
| JP2005527180A (ja) * | 2001-04-18 | 2005-09-15 | プロテイン デザイン ラブス， インコーポレイテッド | 肺がんの診断方法、肺がんの修飾因子の組成及びスクリーニングの方法 |
| JP2005508144A (ja) * | 2001-06-18 | 2005-03-31 | イオス バイオテクノロジー，インコーポレイティド | 卵巣癌の診断方法、卵巣癌のモジュレーターをスクリーニングする組成物及び方法 |
| US20030124579A1 (en) * | 2001-09-05 | 2003-07-03 | Eos Biotechnology, Inc. | Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer |
| JP2005536186A (ja) * | 2002-03-07 | 2005-12-02 | ルードビッヒ、インスティテュート、フォー、キャンサー、リサーチ | リンパ管および血管内皮細胞遺伝子 |
| US20030194704A1 (en) * | 2002-04-03 | 2003-10-16 | Penn Sharron Gaynor | Human genome-derived single exon nucleic acid probes useful for gene expression analysis two |
| US20070015271A1 (en) * | 2002-04-04 | 2007-01-18 | Rosen Craig A | Human secreted proteins |
| CA2500687A1 (en) * | 2002-10-02 | 2004-04-15 | Genentech, Inc. | Compositions and methods for the diagnosis and treatment of tumor |
| CA2507924A1 (en) * | 2002-12-10 | 2004-07-01 | Endocube Sas | Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation |
| WO2004058153A2 (en) * | 2002-12-20 | 2004-07-15 | Millennium Pharmaceuticals, Inc. | Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476. |
| TWI324608B (en) * | 2003-02-28 | 2010-05-11 | Oncotherapy Science Inc | Genes and polypeptides relating to human colorectal cancers |
| WO2005001138A2 (en) * | 2003-06-18 | 2005-01-06 | Arcturus Bioscience, Inc. | Breast cancer survival and recurrence |
| WO2005019258A2 (en) * | 2003-08-11 | 2005-03-03 | Genentech, Inc. | Compositions and methods for the treatment of immune related diseases |
| CN1882698B (zh) * | 2003-08-20 | 2011-05-25 | 肿瘤疗法科学股份有限公司 | 低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶 |
| WO2005083086A2 (en) * | 2004-02-27 | 2005-09-09 | Oncotherapy Science, Inc. | Epha4 as therapeutic target of prc and pdaca |
| EP2495324B1 (en) * | 2004-04-09 | 2015-03-04 | Genecare Research Institute Co., Ltd | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
| JP2008509654A (ja) * | 2004-06-01 | 2008-04-03 | イノジェネティックス・ナムローゼ・フェンノートシャップ | Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド |
| CA2580412A1 (en) | 2004-09-13 | 2006-03-23 | Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services | Compositions comprising t cell receptors and methods of use thereof |
| CN100381460C (zh) * | 2004-11-30 | 2008-04-16 | 北京市肿瘤防治研究所 | Her-2模拟抗原表位及含有该表位的肽 |
| EP1859266A4 (en) * | 2005-02-24 | 2010-07-28 | Cemines Inc | COMPOSITIONS AND METHODS FOR CLASSIFYING BIOLOGICAL SAMPLES |
| PT2325305E (pt) * | 2005-02-25 | 2014-04-29 | Oncotherapy Science Inc | Vacinas peptídicas para cancros do pulmão que expressam polipéptidos ttk, urlc10 ou koc1 |
| CN100348614C (zh) * | 2005-06-03 | 2007-11-14 | 北京大学 | 一种肝癌－睾丸特异性抗原蛋白质和抗原肽 |
| WO2007018047A1 (ja) * | 2005-08-09 | 2007-02-15 | Kurume University | Hla-a24分子結合性扁平上皮癌抗原由来ペプチド |
| EP1923463B1 (en) * | 2005-08-09 | 2011-10-05 | Oncotherapy Science, Inc. | Cancer-rejection antigen peptide derived from glypican-3 (gpc3) for use in hla-a2-positive patient and pharmaceutical comprising the antigen |
| WO2007032255A1 (ja) | 2005-09-13 | 2007-03-22 | Mie University | Ｔ細胞レセプター及び該レセプターをコードする核酸 |
| WO2007064743A2 (en) * | 2005-11-30 | 2007-06-07 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in leukemia signaling pathways |
| WO2007121147A2 (en) * | 2006-04-10 | 2007-10-25 | Genentech, Inc. | Disheveled pdz modulators |
| EP2030984B1 (en) * | 2006-06-16 | 2011-05-11 | Onco Therapy Science, Inc. | Sparc-derived cancer rejection antigen peptide and pharmaceutical comprising the same |
| US20090081659A1 (en) * | 2007-03-07 | 2009-03-26 | Cell Signaling Technology, Inc. | Reagents for the detection of protein phosphorylation in carcinoma signaling pathways |
| EP1983003A3 (en) * | 2007-04-19 | 2009-03-11 | Peter Hornbeck | Tyrosine phosphorylation sites and antibodies specific for them |
| AU2008290060B2 (en) * | 2007-08-20 | 2014-04-24 | Oncotherapy Science, Inc. | CDH3 peptide and medicinal agent comprising the same |
| EP2080812A1 (en) * | 2008-01-18 | 2009-07-22 | Transmedi SA | Compositions and methods of detecting post-stop peptides |
| TWI580431B (zh) * | 2008-08-19 | 2017-05-01 | 腫瘤療法 科學股份有限公司 | Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗 |
| US20120264634A1 (en) * | 2009-09-29 | 2012-10-18 | Protagen Aktiengesellschaft | Marker Sequences for Pancreatic Cancer Diseases, Pancreatic Carcinoma and Use Thereof |
-
2008
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko not_active Abandoned
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko not_active Expired - Fee Related
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active Active
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko not_active Expired - Fee Related
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en not_active Ceased
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en not_active Ceased
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Withdrawn
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko not_active Expired - Fee Related
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
-
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
-
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
-
2012
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
-
2013
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
-
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642B1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
-
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1114590T1 (el) | Εμβολια πεπτιδιου για καρκινους που εκφραζουν ογκο-συναφη αντιγονα | |
| CY1109463T1 (el) | Πεπτιδια kdr και εμβολια που τα περιλαμβανουν | |
| MX2009004147A (es) | Vacunas de peptido para canceres que expresan polipeptidos mphosph1 o depdc1. | |
| NZ601818A (en) | Composition of tumor-associated peptides and related anti-cancer vaccine for the treatment of gastric cancer and other cancers | |
| IL265479B (en) | A fusion containing a cell-penetrating peptide, a multiple epitope, and a peptide tlr agonist for cancer therapy | |
| BR112012029975A2 (pt) | peptídeo como medicamento, em particular para o tratamento do câncer. | |
| BRPI0815578B8 (pt) | Peptídeo de cdca1, seu uso e composição imunogênica compreendendo o mesmo para induzir imunidade, tratar e/ou prevenir o câncer, bem como método in vitro para induzir uma célula apresentadora de antígeno e uma célula t citotóxica (killer) | |
| BR112017027985A2 (pt) | peptídeos terapêuticos e métodos de uso dos mesmos | |
| PE20181897A1 (es) | Inmunoterapia contra el melanoma y otros tipos de cancer | |
| UA100127C2 (ru) | Пептид cdh3 и лекарственное средство, содержащее его | |
| SG10201407944TA (en) | Imp-3 oligopeptides and vaccines including the same | |
| CY1112867T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| MX2012011668A (es) | Peptidos cdca5 y vacunas que incluyen los mismos. | |
| CO6362049A2 (es) | Peptido-epitope rab6kifl/kif20a y vacunas que contienen el mismo | |
| AR113982A1 (es) | Péptido antagonista de la actividad de la interleucina-15 | |
| MX2012006376A (es) | Peptidos mybl2 y vacunas que los contienen. | |
| EA201291004A1 (ru) | Пептиды ect2 и включающие их вакцины | |
| TH120970A (th) | เปปไทด์วัคซีนสำหรับแอนติเจนที่เกี่ยวข้องกับเนื้องอกที่เป็นมะเร็ง | |
| ES2529713T3 (es) | Péptidos anticonceptivos derivados de veneno de araña | |
| CY1114720T1 (el) | Πεπτιδια επιτοπων που προερχονται απο τον υποδοχεα 1 του αγγειακου ενδοθηλιακου αυξητικου παραγοντα και εμβολια περιεχοντας αυτα τα πεπτιδια | |
| EA201300313A1 (ru) | Химерный пептид и фармацевтическая композиция для лечения онкологических заболеваний |